1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Neuland Laboratories Limited

Neuland Laboratories Limited

NEULANDLAB.BO
Neuland Laboratories LimitedIN flagBombay Stock Exchange
18,908.70
INR
+49.75
- -
242.48BMarket Cap
Neuland Laboratories Limited
NEULANDLAB.BO
(Bombay Stock Exchange)

Recent

price

18,908.70

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
607.48
709.05
575.67
587.74
549.22
574.08
507.21
458.1
523.7
576.32
715.65
719.67
904.84
1,181.35
1,151.11
1,576.77
1,576.58
Revenue per Share
8.09
4.05
17.33
33.83
18.67
30.76
42.01
10.81
13.06
12.63
62.85
49.74
127.45
233.89
202.74
283.71
283.68
Basic EPS, GAAP
36.96
69.54
23.47
46.57
-2.66
28.72
-3.4
-109.66
5.4
6.66
65.44
-29.07
133.35
91.59
86.46
-39.32
- -
Free Cash Flow per Basic Share
- -
- -
- -
1.35
3.12
1.8
1.09
- -
- -
3.86
2
3
5
10
14
12
- -
Dividend per Share
18.59
23.25
38.61
66.1
77.68
105.61
125.03
135.84
136.58
142.63
203.48
250.22
372.67
596.56
785.31
10.05
10.05
Book Value per Share
112.72
120.61
124.68
156.09
188.28
247.56
237.43
248.14
332.13
334.02
392.44
435.64
555.99
780.04
966.89
1,238.31
1,238.16
Tangible Book Value per Share
7
6
8
8
9
9
11
11
13
13
13
13
13
13
13
13
13
Basic Weighted Avg Shares
3,969
4,485
4,606
4,657
4,692
5,100
5,658
5,110
6,592
7,394
9,182
9,233
11,609
15,157
14,768
20,230
20,230
Sales/Revenue/Turnover
8.13
7.37
9.61
12.02
11.15
12.76
15.59
5.87
5.83
9.95
11.94
10.41
20.19
26.88
17.45
23.86
23.86
Operating Margin (%)
154
149
146
149
153
157
192
221
259
313
397
490
528
597
655
917
917
Depreciation Expense
53
26
139
268
159
273
469
121
164
162
806
638
1,635
3,001
2,601
3,640
3,640
Net Income, GAAP
- -
- -
14.84
22.57
35.55
35.53
30.25
13.43
19.16
69.37
23.45
22.32
24.21
25.25
24.9
25.56
25.56
Effective Tax Rate (%)
1.33
0.57
3.01
5.76
3.4
5.36
8.28
2.36
2.49
2.19
8.78
6.91
14.09
19.8
17.61
17.99
17.99
Profit Margin (%)
-606
-665
-357
-193
206
495
894
803
1,265
1,576
1,811
2,176
3,219
4,934
6,738
7,729
7,729
Working Capital
716
559
511
339
332
332
298
1,035
607
800
977
1,112
781
541
1,093
2,606
2,606
LT Debt
740
765
1,001
1,242
1,616
4,999
5,456
5,580
6,993
7,100
7,865
8,405
9,941
12,827
15,248
18,745
18,745
Total Equity
- -
- -
13.75
14.9
10.57
8.31
8.77
3.23
3.45
2.38
8.69
7.31
16.1
24.29
12.66
18.56
18.56
Return on Invested Capital (%)
- -
- -
6.66
18.14
11.77
14.81
19.15
5.83
5.6
4.98
20.32
14.18
29.35
42.03
26.3
51.64
51.64
Return on Capital (%)
55.68
19.08
60.82
64.39
26.86
34.12
40.18
8.29
10.17
9.14
36.32
21.93
40.92
48.26
29.34
71.34
71.34
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
742
- -
406
LT Borrowings
892
- -
1,609
LT Finance Leases
1,011
- -
997
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
13
- -
13
Market Capitalization
187,619
194,919
154,140

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
12,656
- -
14,831
Cash, Cash Equivalents & STI
1,797
- -
3,593
Accounts Receivable, Net
4,409
- -
5,414
Inventories
5,479
- -
5,103
Total Current Liabilities
6,443
- -
7,102
Payables & Accruals
- -
- -
- -
ST Debt
742
- -
406
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.5%
19.19%
22.93%
Free Cash Flow
292.33%
-177.11%
-145.49%
Net Income, GAAP
67.5%
49.1%
39.94%
Sales/Revenue/Turnover
15.79%
18.25%
36.98%
Total Cash Common Dividend
- -
48.47%
-14.29%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,630
4,177
3,928
3,421
15,157
2025
4,396
3,108
3,980
3,284
14,768
2026
2,928
5,143
4,397
7,763
20,230

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
48.23
69.56
63.44
- -
233.89
2025
76.28
25.6
79.18
21.67
202.74
2026
10.83
75.49
31.62
165.76
283.71

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
10
2025
- -
- -
- -
- -
14
2026
- -
- -
- -
- -
12
Similar Companies
Jacobson Pharma Corporation Limited (2633.HK)
Zhejiang Hisoar Pharmaceutical Co., Ltd. (002099.SZ)
Solara Active Pharma Sciences Limited (SOLARA.BO)
Livzon Pharmaceutical Group Inc. (LVZPF)
Ilsung Is Co., Ltd. (003120.KS)
4Cable TV International, Inc. (CATV)
Business
Neuland Laboratories Limited manufactures active pharmaceutical ingredients and provides contract development and manufacturing services to the global pharmaceutical industry; its core offerings include custom and specialty APIs across therapeutic areas such as cardiovascular, central nervous system, anti-infectives, asthma, diabetes, and gastroenterology; peptide synthesis using solution-phase and solid-phase techniques; high-potency APIs, complex generics development, and advanced intermediates requiring chiral synthesis, multi-step synthesis, and peptide chemistry; analytical services encompassing method development, validation, stability studies, and impurity profiling; process development, optimization, and regulatory support including Drug Master Files and Certificates of Suitability. The company operates manufacturing facilities in India and the United States, serving over 500 customers in 80 countries with primary markets in the US and Europe, which account for the majority of exports. Founded in 1984 and headquartered in Hyderabad, India, Neuland recently approved a 1.89 billion rupees investment in a new research and development center to enhance innovation capabilities; it completed expansions of manufacturing facilities positioning for growth in FY26, particularly in high-value peptides and early-stage biotech projects amid rising interest from larger firms and favorable US funding trends.